SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026

Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis.

What the trial testedrandomised · 49,847 people · 2026

Randomised comparison

−22%−34% to −7%

Bigger than 5 in 10 for cardiovascular events

As reported

RR 0.78, 95% CI 0.66–0.93

Randomised comparison

−53%−75% to −14%

Bigger than 9 in 10 for cardiovascular events

As reported

RR 0.47, 95% CI 0.25–0.86

the abstract, start to end

… compared with placebo (risk ratios (RR): 0.78, 95% confidence intervals (CI): 0.66-0.93 and RR: 0.47, 95% CI 0.25-0.86, …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

RR 0.780.66–0.93

Cardiovascular events

RR 0.470.25–0.86

PCSK9 inhibitorsCardiovascular events

PCSK9 inhibitors × cardiovascular eventshelps?settled

unlikelylikely

1.00not counted

← favours treatmentfavours comparator →

more certainless certain

1 / 5

2026

this papercites it